- Home
- CRVO vs PCM Comparison
CRVO vs PCM Comparison
Compare CRVO & PCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- PCM
- Stock Information
- Founded
- CRVO 2001
- PCM 1993
- Country
- CRVO United States
- PCM United States
- Employees
- CRVO N/A
- PCM N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- PCM Trusts Except Educational Religious and Charitable
- Sector
- CRVO Health Care
- PCM Finance
- Exchange
- CRVO Nasdaq
- PCM Nasdaq
- Market Cap
- CRVO 67.4M
- PCM 77.7M
- IPO Year
- CRVO N/A
- PCM N/A
- Fundamental
- Price
- CRVO $6.96
- PCM $6.37
- Analyst Decision
- CRVO Strong Buy
- PCM
- Analyst Count
- CRVO 7
- PCM 0
- Target Price
- CRVO $19.33
- PCM N/A
- AVG Volume (30 Days)
- CRVO 162.5K
- PCM 29.1K
- Earning Date
- CRVO 08-08-2025
- PCM 01-01-0001
- Dividend Yield
- CRVO N/A
- PCM 11.68%
- EPS Growth
- CRVO N/A
- PCM N/A
- EPS
- CRVO N/A
- PCM N/A
- Revenue
- CRVO $9,308,215.00
- PCM N/A
- Revenue This Year
- CRVO N/A
- PCM N/A
- Revenue Next Year
- CRVO N/A
- PCM N/A
- P/E Ratio
- CRVO N/A
- PCM N/A
- Revenue Growth
- CRVO 15.14
- PCM N/A
- 52 Week Low
- CRVO $1.80
- PCM $6.88
- 52 Week High
- CRVO $20.63
- PCM $10.20
- Technical
- Relative Strength Index (RSI)
- CRVO 51.63
- PCM 52.89
- Support Level
- CRVO $5.45
- PCM $6.26
- Resistance Level
- CRVO $7.55
- PCM $6.49
- Average True Range (ATR)
- CRVO 0.59
- PCM 0.05
- MACD
- CRVO 0.14
- PCM 0.01
- Stochastic Oscillator
- CRVO 75.71
- PCM 47.83
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.